Evommune (NYSE:EVMN) Now Covered by Oppenheimer

Oppenheimer assumed coverage on shares of Evommune (NYSE:EVMN) in a research report released on Tuesday. The firm issued an outperform rating and a $50.00 price target on the stock.

EVMN has been the topic of a number of other research reports. Evercore reissued an “outperform” rating and issued a $55.00 target price on shares of Evommune in a report on Tuesday, February 10th. Weiss Ratings started coverage on Evommune in a report on Tuesday, February 3rd. They issued a “sell (e)” rating on the stock. Morgan Stanley reissued an “overweight” rating and issued a $54.00 target price on shares of Evommune in a report on Wednesday, February 18th. HC Wainwright dropped their target price on Evommune from $65.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, Royal Bank Of Canada raised Evommune to a “moderate buy” rating in a report on Tuesday, March 10th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.50.

Evommune Stock Performance

Shares of NYSE EVMN opened at $24.78 on Tuesday. Evommune has a twelve month low of $13.89 and a twelve month high of $33.20. The company has a 50 day moving average price of $24.27. The stock has a market capitalization of $892.47 million and a PE ratio of -3.07.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.61).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of EVMN. EQT Fund Management S.a r.l. acquired a new position in Evommune during the fourth quarter worth $84,395,000. RA Capital Management L.P. acquired a new position in Evommune during the fourth quarter worth $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in Evommune during the fourth quarter worth $32,989,000. Nan Fung Group Holdings Ltd acquired a new position in Evommune during the fourth quarter worth $24,670,000. Finally, JPMorgan Chase & Co. acquired a new position in Evommune during the fourth quarter worth $22,408,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.